A Multidisciplinary Approach to CAR T-cell Therapy for Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia - Episode 12

Future Considerations for Treatment Sequencing in B-ALL

April 4, 2025

Bijal Shah, MD, MS, Katherine (Katie) Tobon, PharmD, Brenna Williams, FNP-C, APRN-NPI, Joshua Abrahan, BSN, RN

Experts share their final thoughts on the unmet needs and future perspectives of chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies, emphasizing areas for improvement and potential advancements in treatment.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: CAR T-cell Therapy for B-ALL

EP. 2: Navigating Treatment Selections for B-ALL: Insights From the Moffitt Cancer Center

EP. 3: The Multidisciplinary Approach to CAR T-Cell Therapy for B-ALL

EP. 4: CAR T-Cell Therapy for B-ALL: Roles Within the Multidisciplinary Care Team

EP. 5: Optimizing Molecular Profiling for B-ALL Treatment

EP. 6: Multidisciplinary Clinical Perspectives: Factors That Influence CAR T-Cell Sequencing in B-ALL

EP. 7: Considerations Regarding Bridging Therapy for B-ALL CAR T-Cell Treatment

EP. 8: Obe-Cel for B-ALL: Insights Regarding Persistence, Toxicity, and Remission

EP. 9: CAR T-Cell Therapy Decisions in B-ALL: The Role of Obe-Cel in B-ALL Treatment

EP. 10: Managing Immunotoxicities With CAR T-Cell Therapy for B-ALL

EP. 11: Treatment Sequencing Decisions for B-ALL: Perspectives From Moffitt Cancer Center

Now Viewing

EP. 12: Future Considerations for Treatment Sequencing in B-ALL

Video content above is prompted by the following:

Thank you for this dynamic and informative discussion. Before we conclude, please share your final thoughts on the unmet needs and future perspectives of CAR T-cell therapy for hematologic malignancies.